The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with combination of immunotherapy with chemotherapy: Preliminary results from a European retrospective study.
 
Foteinos-Ioannis D. Dimtrakopoulos
No Relationships to Disclose
 
Petros Christopoulos
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novartis; Pfizer; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); Roche (Inst); Takeda (Inst)
 
Mariam Elshiaty
No Relationships to Disclose
 
Lea Daniello
No Relationships to Disclose
 
Ioannis Pyrousis
No Relationships to Disclose
 
Anastasia E Kottorou
No Relationships to Disclose
 
Thomas Makatsoris
Honoraria - AstraZeneca; Genesis Pharma; Ipsen; Merck; MSD; Sanofi Aventis GmbH
 
Haralabos Kalofonos
Consulting or Advisory Role - Amgen; EMD Serono; Genesis Pharma; Janssen Biotech; Leo Pharma; Lilly; MSD/Merck; Novartis; Pfizer; Roche
Research Funding - Amgen; Bayer; EMD Serono; Genesis Pharma; Janssen Biotech; Lilly; MSD/Merck; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche
 
Angelos Koutras
Consulting or Advisory Role - Pierre Fabre
Travel, Accommodations, Expenses - Genesis Pharmaceuticals; Ipsen; MSD